Tsai-Yuan Hsieh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9197788/publications.pdf

Version: 2024-02-01

59	830	13	27
papers	citations	h-index	g-index
60	60	60	1410 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. Gut, 2022, 71, 176-184.	6.1	28
2	Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR). Clinical Gastroenterology and Hepatology, 2022, 20, 1151-1162.e6.	2.4	14
3	Successful treatment of chronic hepatitis C virus infection with crushed elbasvir/grazoprevir administered through a nasogastric tube in a patient with hypoxic encephalopathy. Kaohsiung Journal of Medical Sciences, 2022, 38, 77-78.	0.8	O
4	Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. World Journal of Gastroenterology, 2022, 28, 263-274.	1.4	10
5	Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan. Journal of the Formosan Medical Association, 2022, 121, 1567-1578.	0.8	2
6	Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. Viruses, 2022, 14, 333.	1.5	2
7	Sofosbuvir/Velpatasvir for HepatitisÂC Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. Infectious Diseases and Therapy, 2022, 11, 485-500.	1.8	13
8	Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan. Hepatology International, 2021, 15, 338-349.	1.9	20
9	Factors associated with treatment failure of directâ€acting antivirals for chronic hepatitis C: A realâ€world nationwide hepatitis C virus registry programme in Taiwan. Liver International, 2021, 41, 1265-1277.	1.9	29
10	Safety Issues in Magnetic Resonance Imaging Scan with Retention of Olympus Long Clips in the Gastrointestinal Tract. Current Medical Imaging, 2021, 17, 1243-1247.	0.4	0
11	Tacrolimus concentrations were not affected by glecaprevir/pibrentasvir treatment for hepatitis C virus infection in an adult living donor liver transplant recipient with uremia. Journal of the Formosan Medical Association, 2021, 120, 1408-1409.	0.8	1
12	Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. Clinical and Molecular Hepatology, 2021, 27, 575-588.	4.5	9
13	CRNDE-h transcript/miR-136-5p axis regulates interleukin enhancer binding factor 2 expression to promote hepatocellular carcinoma cell proliferation. Life Sciences, 2021, 284, 119708.	2.0	7
14	SPAK Deficiency Attenuates Chemotherapy-Induced Intestinal Mucositis. Frontiers in Oncology, 2021, 11, 733555.	1.3	1
15	Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. Scientific Reports, 2021, 11, 23473.	1.6	8
16	Upregulation of amphiregulin by retinoic acid and Wnt signalling promotes liver cancer cell proliferation. Journal of Cellular Physiology, 2020, 235, 1689-1699.	2.0	2
17	Flare of hepatitis B virus after fingolimod treatment for relapsing and remitting multiple sclerosis. Journal of the Formosan Medical Association, 2020, 119, 886-887.	0.8	6
18	Impact of endoscopic sedation on gastric polyp detection: A one-center retrospective observational study. Medicine (United States), 2020, 99, e22556.	0.4	1

#	Article	IF	Citations
19	Nonalcoholic Fatty Liver Disease Associated With Bladder Cancer. American Journal of the Medical Sciences, 2020, 360, 161-165.	0.4	8
20	Fecaloma impaction and stercoral ulcer. Advances in Digestive Medicine, 2020, 7, 166-169.	0.1	1
21	Relationships Between Vitamin D Status and Cytokine: Results from Interferon-Based Therapy in Non-Cirrhotic, Treatment-NaÃ-ve Patients with Chronic Hepatitis C Infection. Journal of Inflammation Research, 2020, Volume 13, 1207-1218.	1.6	1
22	Endoscopic resection for superficial hypopharyngeal/laryngeal cancer and clinical pathway options. Advances in Digestive Medicine, 2019, 6, 123-127.	0.1	0
23	Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study. Journal of the Formosan Medical Association, 2019, 118, 1014-1023.	0.8	9
24	YC-1 Antagonizes Wnt $\hat{\Pi}^2$ -Catenin Signaling Through the EBP1 p42 Isoform in Hepatocellular Carcinoma. Cancers, 2019, 11, 661.	1.7	6
25	Early Initiation of Post-Pyloric Feeding in Patients with Major Burns: Experience in Taiwan Formosa Water Park Dust Explosion Disaster. Tohoku Journal of Experimental Medicine, 2019, 247, 111-118.	0.5	5
26	An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE) Tj ETQq0	0 0 ₁ .gBT /0	Overlock 10 Ti
27	Infectious Diseases, 2019, 220, 557-566. Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian nonâ€cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1977-1983.	1.4	7
28	Is a bleeding scan prior to single-balloon enteroscopy necessary in patients with obscure gastrointestinal bleeding?. Journal of the Formosan Medical Association, 2019, 118, 1031-1037.	0.8	1
29	Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey. Internal and Emergency Medicine, 2018, 13, 191-197.	1.0	24
30	Salvage nasoduodenal feeding for severely burned patients after the failure of nasogastric feeding: A medical center experience in a mass casualty burn disaster. Advances in Digestive Medicine, 2018, 5, 132-136.	0.1	0
31	Concomitant use of direct-acting antiviral agents and chemotherapy in hepatitis CÂvirus reactivation. Journal of the Formosan Medical Association, 2018, 117, 1034-1035.	0.8	1
32	Comorbidities, concomitant medications and potential drugâ€drug interactions with interferonâ€free directâ€acting antiviral agents in hepatitis C patients in Taiwan. Alimentary Pharmacology and Therapeutics, 2018, 48, 1290-1300.	1.9	43
33	Long-term outcomes in elderly patients with resectable large hepatocellular carcinoma undergoing hepatectomy. Surgical Oncology, 2018, 27, 595-601.	0.8	9
34	HCV core inhibits hepatocellular carcinoma cell replicative senescence through downregulating microRNA-138 expression. Journal of Molecular Medicine, 2017, 95, 629-639.	1.7	16
35	A case of a large colonic lipoma resected by endoscopic submucosal dissection: A longâ€ŧerm endoscopic observation. Advances in Digestive Medicine, 2017, 4, 114-116.	0.1	0
36	Singleâ€balloon enteroscopy for managing obscure gastrointestinal bleeding: Results from a tertiary medical center in Taiwan. Advances in Digestive Medicine, 2017, 4, 18-25.	0.1	0

#	Article	IF	Citations
37	The role of thiazolidinediones in hepatocellular carcinoma risk reduction: a population-based cohort study in Taiwan. American Journal of Cancer Research, 2017, 7, 1606-1616.	1.4	13
38	Outcome and Safety of Anterograde and Retrograde Single-Balloon Enteroscopy: Clinical Experience at a Tertiary Medical Center in Taiwan. PLoS ONE, 2016, 11, e0161188.	1.1	9
39	Efficacy of entecavir therapy for hepatitis B eâ€antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues. Hepatology Research, 2016, 46, 642-649.	1.8	1
40	Outcome of nonsurgical intervention in patients with perforated peptic ulcers. American Journal of Emergency Medicine, 2016, 34, 1556-1560.	0.7	10
41	Quantitative methylation analysis reveals distinct association between PAX6 methylation and clinical characteristics with different viral infections in hepatocellular carcinoma. Clinical Epigenetics, 2016, 8, 41.	1.8	11
42	Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg. American Journal of Gastroenterology, 2016, 111, 1286-1294.	0.2	57
43	Fourâ€year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver International, 2016, 36, 1755-1764.	1.9	177
44	Hepatic cystic metastatic tumors from a locally controlled nasopharyngeal carcinoma. Advances in Digestive Medicine, 2016, 3, 69-72.	0.1	3
45	Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan. Hepatology International, 2016, 10, 294-301.	1.9	3
46	Restriction fragment length polymorphism effectively identifies exon 1 mutation of <scp>UGT</scp> 1A1 gene in patients with Gilbert's Syndrome. Liver International, 2015, 35, 2050-2056.	1.9	14
47	HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients. Journal of the Formosan Medical Association, 2015, 114, 308-313.	0.8	11
48	Simultaneous splenectomy during liver transplantation augments anti-viral therapy in patients infected with hepatitis C virus. American Journal of Surgery, 2015, 209, 180-186.	0.9	11
49	Factors Influencing Cecal Intubation Time during Retrograde Approach Single-Balloon Enteroscopy. Gastroenterology Research and Practice, 2014, 2014, 1-5.	0.7	1
50	Younger age and female sex predict a better therapeutic response in HBeAgâ€positive chronic hepatitis B patients to entecavir therapy. Advances in Digestive Medicine, 2014, 1, 112-117.	0.1	1
51	Singleâ€balloon enteroscopyâ€assisted nasojejunal tube placement. Advances in Digestive Medicine, 2014, 1, 30-32.	0.1	0
52	Liver cirrhosis as a predisposing factor for esophageal candidiasis. Advances in Digestive Medicine, 2014, 1, 86-91.	0.1	6
53	Benefits of the povidone–iodine: Simultaneously decrease risk of infection and tumor seeding after percutaneous endoscopic gastrostomy. Medical Hypotheses, 2014, 82, 678-680.	0.8	2
54	Unusual computed tomography features of ruptured sarcomatous hepatocellular carcinoma. Journal of the Chinese Medical Association, 2014, 77, 265-268.	0.6	10

#	Article	IF	CITATIONS
55	Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan. Journal of the Formosan Medical Association, 2014, 113, 727-733.	0.8	9
56	Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study. Journal of Hepatology, 2012, 56, 1097-1103.	1.8	91
57	Physical and functional interactions between hnRNP K and PRMT family proteins. FASEB Journal, 2010, 24, 713.3.	0.2	O
58	Molecular pathogenesis of Gilbert's syndrome: decreased TATA-binding protein binding affinity of UGT1A1 gene promoter. Pharmacogenetics and Genomics, 2007, 17, 229-236.	0.7	63
59	The first hydrophobic domain of the hepatitis C virus E1 protein is important for interaction with the capsid protein. Journal of General Virology, 2002, 83, 3085-3092.	1.3	28